Besunyen Holdings Company Limited (HKG:0926)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 299.55M +9.9% |
| Revenue (ttm) | 550.09M +2.1% |
| Net Income | 22.75M +38.1% |
| EPS | 0.19 +39.3% |
| Shares Out | 122.27M |
| PE Ratio | 13.17 |
| Forward PE | n/a |
| Dividend | 0.15 (6.15%) |
| Ex-Dividend Date | Aug 27, 2025 |
| Volume | 400 |
| Open | 2.440 |
| Previous Close | 2.440 |
| Day's Range | 2.440 - 2.440 |
| 52-Week Range | 2.210 - 3.420 |
| Beta | 1.17 |
| Analysts | Strong Buy |
| Price Target | 133.11 (+5,355.33%) |
| Earnings Date | Aug 5, 2026 |
About Besunyen Holdings Company
Besunyen Holdings Company Limited manufactures and sells therapeutic tea products and pharmaceuticals in the People’s Republic of China. It operates through Tea Products; and Weight-Loss and Other Medicines segments. The company offers therapeutic tea products, such as detox, slimming, fit, and relief tea under the Besunyen brand, as well as other tea products. It also provides Besunyen Orlistat weight-loss medicines, nutrition meal replacements, probiotics, and enzymes. The company sells its products through over-the-counter pharmacies, pharma... [Read more]
Financial Performance
In 2025, Besunyen Holdings Company's revenue was 494.32 million, an increase of 2.07% compared to the previous year's 484.30 million. Earnings were 20.44 million, an increase of 38.09%.
Financial numbers in CNY Financial StatementsNews
Dietary Drugs Restore Besunyen's Fiscal Health In H1-25
Once a household name known for its ‘slimming tea,' the company is looking for a new formula in dietary drugs after years of losses and asset sales Key Takeaways: Besunyen logged a net profit of 12.4 ...